24134-65-4

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzimidazole-5-sulfonyl chloride (SALTDATA: FREE) is utilized as a reagent in organic synthesis for the preparation of a variety of pharmaceuticals and agrochemicals. Its unique structure and reactivity contribute to the development of new compounds with potential therapeutic and pesticidal properties.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzimidazole-5-sulfonyl chloride (SALTDATA: FREE) is studied for its potential as an anti-inflammatory and anti-cancer agent. Its ability to form new chemical entities makes it a promising candidate for the treatment of various diseases.
Used in Laboratory Settings with Precaution:
Due to its strong irritant properties, 1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzimidazole-5-sulfonyl chloride (SALTDATA: FREE) should be handled with care in a controlled laboratory environment. Proper safety measures and equipment are essential to ensure the well-being of researchers and the integrity of experiments.

Upstream product

• 3097-21-0 1,3-dimethyl-1,3-dihydrobenzimidazol-2-one 

Downstream Products

• 956467-51-9 N-methyl-N-{2-[{[3,4-bis(methyloxy)phenyl]sulfonyl}(methyl)amino]ethyl}-1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzimidazole-5-sulfonamide 
• 1146895-98-8 5-(4-(4-acetylphenyl)piperazin-1-ylsulfonyl)-1,3-dimethyl-1H-benzo[d]imidazol-2(3H)-one 

Relevant academic research and scientific papers

Benzylpiperidine-benzimidazole derivative or pharmaceutically acceptable salt thereof, and preparation method and application thereof

The invention discloses a benzylpiperidine-benzimidazole derivative with a structure as shown in a general formula (I) or a pharmaceutically acceptable salt thereof, and a preparation method and application thereof. The derivative disclosed by the invention has good cholinesterase inhibition activity, can be used for preparing cholinesterase inhibitors, and is of important significance to treatment of neurodegenerative diseases.

Design, synthesis, in vitro and in vivo evaluation of benzylpiperidine-linked 1,3-dimethylbenzimidazolinones as cholinesterase inhibitors against Alzheimer’s disease

Cholinesterase inhibitor plays an important role in the treatment of patients with Alzheimer’s disease (AD). Herein, we report the medicinal chemistry efforts leading to a new series of 1,3-dimethylbenzimidazolinone derivatives. Among the synthesised compounds, 15b and 15j showed submicromolar IC50 values (15b, eeAChE IC50 = 0.39 ± 0.11 μM; 15j, eqBChE IC50 = 0.16 ± 0.04 μM) towards acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Kinetic and molecular modelling studies revealed that 15b and 15j act in a competitive manner. 15b and 15j showed neuroprotective effect against H2O2-induced oxidative damage on PC12 cells. This effect was further supported by their antioxidant activity determined in a DPPH assay in vitro. Morris water maze test confirmed the memory amelioration effect of the two compounds in a scopolamine-induced mouse model. Moreover, the hepatotoxicity of 15b and 15j was lower than tacrine. In summary, these data suggest 15b and 15j are promising multifunctional agents against AD.

Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy

Tryptophan metabolism has been recognized as an important mechanism in immune tolerance. Indoleamine 2,3-dioxygenase plays a key role in local tryptophan metabolism via the kynurenine pathway and has emerged as a therapeutic target for cancer immunotherapy. Our prior study identified phenyl benzenesulfonyl hydrazide 2 as a potent in vitro (though not in vivo) inhibitor of indoleamine 2,3-dioxygenase. Further lead optimization to improve in vitro potencies and pharmacokinetic profiles resulted in N′-(4-bromophenyl)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl hydrazide 40, which demonstrated 59% oral bioavailability and 73% of tumor growth delay without apparent body weight loss in the murine CT26 syngeneic model, after oral administration of 400 mg/kg. Accordingly, 40, is proposed as a potential drug lead worthy of advanced preclinical evaluation.

CHEMICAL COMPOUNDS

The present invention relates generally to novel therapeutic compounds and AXOR 109 agonists, and processes for the manufacture and use of the same.